Among the group’s sterling researchers are Dr. Lorne Tyrrell, inventor of the Hepatitis B vaccine, and the co-discoverer of the Hepatitis C virus, Dr. Michael Houghton.
To translate that knowledge into practical disease-fighting products, a new University of Alberta spin-off company Prophysis was created.
TEC Edmonton is assisting Prophysis with business development and market research, plus lending its patenting and licensing expertise to the company.
To date, two potential products have been patented. Dr. Luis Schang’s research into anti-viral compounds known as RAFIs could lead to treatment for a wide range of virus-caused afflictions. Patents have been granted in the USA, China and Japan, and are under examination in other jurisdictions. Dr. David Evans’ oncolytics program has proven effective in treating cancer tumours in animal models. The process has received a USA patent, and will now undergo regulatory review of its safety in humans.
Other potential Prophysis products include new anti-virals developed through advanced computer technology, processes to analyse drug toxicity, and new systems to diagnose liver diseases.